SCHEMBL14719672

SCHEMBL14719672

N#Cc1ccc(C#Cc2cc(OCc3ccccc3)c(OCc3ccccc3)nn2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.51
SQOR Q9Y6N5 1/20 0.44
GABRG2 P18507 3/20 0.40
GABRB3 P28472 3/20 0.40
GABRA5 P31644 3/20 0.40
GABRA3 P34903 3/20 0.40
EGLN2 Q96KS0 1/20 0.40
PPIA P62937 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
AR P10275 1/20 0.39
CYP19A1 P11511 1/20 0.39
GABRA1 P14867 2/20 0.39
GABRA2 P47869 2/20 0.39
MRGPRX4 Q96LA9 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14719454 0.91 L3MBTL1 (0.41) SQORMAPK1
SCHEMBL14719169 0.89 MAPT (0.40) SQORALDH1A1POLBMAPK1
SCHEMBL14718339 0.88 CNR1 (0.41) PPIAMAPK1
SCHEMBL14718952 0.83 ABCB1 (0.45) KDM4EALDH1A1HPGDHSD17B10MRGPRX4
SCHEMBL14719133 0.83 PTGER1 (0.38) MAOBSQORMAPK1MRGPRX4
SCHEMBL14718770 0.82 PTGER1 (0.38) SQORPPIAPOLBMAPK1
SCHEMBL14719573 0.82 FFAR1 (0.47) MAOBMRGPRX4
SCHEMBL14719176 0.82 MRGPRX4 (0.42) MAOBALDH1A1POLBMRGPRX4
SCHEMBL14729732 0.82 MAOB (0.54) MAOBSQORGABRG2GABRB3GABRA5
SCHEMBL14718654 0.81 GRM5 (0.41) PPIAKDM4EHPGDMAPK1MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-01-07 US disclosed
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-13 US disclosed
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-13 US disclosed
US-11129828-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-09-28 US disclosed
US-11129828-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-09-28 US disclosed
US-20200121678-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2020-04-23 US disclosed
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-11-05 US disclosed
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-11-05 US disclosed
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-28 US disclosed
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-28 US disclosed
EP-2748149-B1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2015-10-21 EP disclosed
EP-2748149-B1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2015-10-21 EP disclosed
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-29 US disclosed
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-29 US disclosed
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-29 US disclosed
EP-2748149-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2014-07-02 EP disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed
WO-2013027000-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed
WO-2013027000-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052281-A1 NOVEL COMPOUNDS ABCG2, F12, UGT1A1 MAOB 1294/4885SQOR 502/4885GABRG2 1858/4885
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD MAOB 12/4885SQOR 92/4885GABRG2 4114/4885
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD MAOB 12/4885SQOR 92/4885GABRG2 4114/4885
US-20200121678-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD MAOB 12/4885SQOR 92/4885GABRG2 4114/4885
US-11129828-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD MAOB 12/4885SQOR 92/4885GABRG2 4114/4885
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD MAOB 12/4885SQOR 92/4885GABRG2 4114/4885
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD MAOB 12/4885SQOR 92/4885GABRG2 4114/4885
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD MAOB 12/4885SQOR 92/4885GABRG2 4114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.